Vir Biotechnology (VIR) Other Non-Current Liabilities (2018 - 2026)

Vir Biotechnology has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $33.2 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $33.2 million, up 40.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.2 million (up 40.48% YoY), and the FY2025 annual result was $21.6 million, down 10.28% from the prior year.
• Other Non-Current Liabilities came in at $33.2 million for Q1 2026 at Vir Biotechnology, up from $21.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $34.2 million in Q3 2025 to a low of $7.2 million in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $24.9 million (2023), against an average of $23.7 million.
• Across the five-year window, Other Non-Current Liabilities jumped 638.52% in 2022 and sank 56.41% in 2023, its largest moves.
• Vir Biotechnology's Other Non-Current Liabilities stood at $24.9 million in 2022, then sank by 36.7% to $15.8 million in 2023, then soared by 52.37% to $24.0 million in 2024, then decreased by 10.28% to $21.6 million in 2025, then soared by 53.91% to $33.2 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $33.2 million (Q1 2026), $21.6 million (Q4 2025), and $34.2 million (Q3 2025), per Business Quant data.